KRAS and cancer: Thus, amplifications of wt RAS genes are much more prevalent in MT-L tumors (p = 3.7E − 04 for KRAS, and p = 8.3E − 05 for all RAS genes combined) and comprise a much higher fraction of total RAS gene alterations in MT-L tumors (Fig. 5a), although the numbers did not reach statistical significance except for HRAS (p = 8.4E −04).